FDA Commissioner Scott Gottlieb, MD, announced the release of the agency’s Biosimilar Action Plan; Philadelphia’s tax on soda and other sweetened beverages has been upheld by the Pennsylvania Supreme Court; a federal judge dismissed a lawsuit by 19 states against the Trump administration over the decision to end cost-sharing subsidies under the Affordable Care Act.
FDA Commissioner Scott Gottlieb, MD, announced the release of the agency’s Biosimilar Action Plan. According to The Center for Biosimilars®, a sister website of The American Journal of Managed Care®, the plan addresses 4 key areas and is meant to spur biosimilar competition in the US marketplace. While potential savings from biosimilars have been estimated to be as much as $54 billion between 2017 and 2026, the real savings have been just a fraction of even the most conservative estimates, Gottlieb noted. He blamed litigation for delaying market access of biosimilar products and preventing competition.
Philadelphia’s tax on soda and other sweetened beverages has been upheld by the Pennsylvania Supreme Court. The court ruled the city can tax the distribution of beverages even as opponents of the tax argued it was double taxation, reported The Philadelphia Inquirer. The 1.5-cent-per-ounce tax will fund pre-K, community schools, and improvements to parks, libraries, and recreation centers.
A lawsuit against the Trump administration over its decision to end cost-sharing subsidies under the Affordable Care Act was dismissed by a federal judge in California. The lawsuit was brought by 19 states, led by California, in October 2017, but on Monday the states asked the judge to stay or dismiss the lawsuit entirely, according to The Associated Press. The states said they had since found a workaround to protect consumers from higher costs by allowing insurers to raise premiums on some plans so consumers could get access to additional tax credits.
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
Rozanolixizumab Effective in Patients with MuSK MG, Analysis Shows
October 23rd 2024A new subgroup analysis of patients with muscle-specific tyrosine kinase (MuSK) autoantibody-positive (Ab+) myasthenia gravis (MG) shows rozanolixizumab (Rystiggo) contributes to meaningful symptom improvement.
Read More
Frameworks for Advancing Health Equity: Community Wellness Centers
September 27th 2024Delia Orosco, MS, director of Community Wellness Centers at Inland Empire Health Plan, shares insight into innovative initiatives provided by the wellness centers and their new mobile mammogram clinics.
Listen